Mark McDade is a prominent figure in the healthcare and life sciences sector, currently serving as a Co-Founder and Partner at Qiming Venture Partners USA. With a career spanning over three decades, he has amassed extensive experience in both private and public companies within the industry. McDade's educational background includes a Bachelor of Arts in History from Dartmouth College and an MBA from Harvard Business School, equipping him with a solid foundation for his diverse professional roles. Before co-founding Qiming Venture Partners USA in January 2017, McDade held several executive positions. He was the Executive Vice President and Chief Operating Officer at UCB, a global biopharma company based in Brussels. His leadership journey also includes serving as CEO and Director of PDL Biopharma, CEO of Signature Bioscience, and co-founder of Corixa Corporation, where he held the roles of COO and President. McDade's contributions extend to board memberships, where he plays a pivotal role in guiding several of Qiming's portfolio companies. He is the Chairman of the Board at Icosavax and has previously chaired Aimmune Therapeutics and served as a director at Dermira, Inc. Additionally, he is a director at Lupin Ltd. and a trustee of the National Marine Sanctuary Foundation. His vast experience and strategic insights have made him a key player in the venture capital and healthcare industries.